How much do you know about the new metric reshaping CGM data in diabetes care?
Since its introduction in 2022, the Glycemia Risk Index (GRI) has gained traction in the endocrinology community as a promising new metric for diabetes management.
Yet, despite its potential, GRI remains underutilized—particularly as a critical component of the Ambulatory Glucose Profile (AGP) report.
However, integrating GRI into CGM data analysis can provide deeper insights for both in-person patient conversations and remote diabetes management, helping clinicians make more informed decisions.
In this webinar, you'll explore the latest research on GRI’s impact and hear from a practicing endocrinologist with a vision for leveraging GRI within the AGP report.
Can't join live? Register in advance, and you'll receive a recording after the event.
I want to join the webinar!
.png)
Featured Speakers
David Klonoff, MD
Founder of the Glycemia Risk Index (GRI)
Dr. David Klonoff is an endocrinologist specializing in the development and use of diabetes technology. He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center and a Clinical Professor of Medicine at UCSF. He is the Founding Editor-in-Chief of Journal of Diabetes Science and Technology and he previously founded Diabetes Technology & Therapeutics. He received the American Diabetes Association’s Outstanding Physician Clinician Award in 2019. Dr. Klonoff developed the Glycemia Risk Index, a metric for assessing glycemic quality in continuous glucose monitor tracings.
Ralph Oiknine, MD
Founder and Chief Medical Officer, SweetSpot
Dr. Ralph Oiknine is an endocrinologist, physician founder, and Chief Medical Officer of SweetSpot. He also leads his own practice, Diabetes & Endocrinology Specialists, in Missouri. Most recently, Dr. Oiknine published a Letter to the Editor in the Journal of Diabetes Science and Technology highlighting the potential use of the Glycemia Risk Index (GRI) in personalized medicine.